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Sir,
Recent studies have focused on the possible prognostic
importance of lymphatic vessel density (LVD) in malignant
melanoma, and we have read the paper by Shields et al (2004)
with great interest. Based on their data, the authors suggest that the
assessment of lymphatic vessel density (LVD) might give
prognostic information in cutaneous melanoma. As they point
out, some conclusions of their study might, in part, be in
discordance with our own report (Straume et al, 2003), and we
would therefore like to discuss some aspects of their work.
So far, relatively few survival studies on lymphangiogenesis have
been published. In 2001, Birner et al (2001) presented a study on
cervical cancer, and later our group published the first survival
study of melanomas, based on 175 cases of aggressive vertical
growth phase melanoma of the nodular type (median thick-
ness 3.6mm) (Straume et al, 2003). The results of both these
studies indicate that increased LVD is associated with improved
patient survival. More recently, however, Valencak et al (2004)
published a prognostic study of 120 melanoma patients showing a
weak association between increased LVD and reduced survival,
although in univariate analysis only. In a study by Dadras et al
(2003), based on the selection of 19 nonmetastatic melanoma
patients and 18 patients with early lymph node metastasis,
intratumour LVD was found to be increased in the metastatic
group. In the study of Shields et al, including 21 melanoma
cases (eight nonmetastatic, mean thickness 2.3mm, and 11
metastatic, mean thickness 3.4mm), LVD was also higher in
tumours that developed metastases. Interestingly, LVD tended to
decrease with increasing tumour thickness (their Table 2). No
follow-up information (time to events) was presented. Whereas
these three studies (Dadras et al, 2003; Shields et al, 2004; Valencak
et al, 2004) seem to imply that increased LVD is associated
with tumour progression and poor prognosis, the contrary was
found in our own study (Straume et al, 2003). What could explain
this difference?
Several explanations might be considered. We agree with Shields
et al that the ‘hot spot’ technique, originally described by Weidner
et al (1991) for the estimation of angiogenesis, might be more
applicable for blood microvascular capillaries, and this approach is
more subjective. The authors discuss whether some of the
differences in our results could be attributed to this fact. Although
our two studies showed comparable values of mean epi/peri-
tumoral LVD (10.0 vs 14.3mm
 2), we wanted to address this issue
and selected 19 lethal and 21 nonlethal melanoma cases from our
series (Straume et al, 2003), and tumours were matched for
thickness. Lymphatic vessels were counted along the complete
tumour border in consecutive high power fields (HPF,  400), and
vessels more than 1 HPF away from the invasive border were not
counted. We found that the median absolute LVD (LVD-ABS) was
5.4vesselsmm
 2 compared with 12.5mm
 2 by the ‘hot spot’
technique (LVD-HS) (7.0 in nonlethal cases, 3.4 in lethal cases),
and LVD-ABS and LVD-HS were highly correlated (linear
regression R¼0.74, Po0.001 for continuous variables, and
Pearson w
2 R¼0.7, Po0.001 when categorised between lymphatic
vessel rich or poor cases). Most importantly, the analysis of both
overall survival (melanoma deaths only) and recurrence-free
survival showed the same association for both LVD-ABS and
LVD-HS, that is, improved survival by increased LVD-ABS (log
rank P¼0.005, n¼40) and increased LVD-HS (log rank
Po0.0001, n¼169). These data indicate that the difference in
results cannot be explained by the difference in counting technique
only. Still, we agree that LVD-ABS might be more appropriate and
more easily standardised than LVD-HS, as suggested by Shields.
In the study by Dadras et al (2003), 18 metastatic and 19
nonmetastatic melanomas were included (mean thickness 2.5mm,
68% Clark 4–5; mainly (76%) superficial spreading melanomas).
The median peritumoral LVD (12.8mm
 2) was almost identical
with our own findings (12.5mm
 2), suggesting that both methods
(Dadras: computer-assisted morphometric analysis; Straume:
counting in ‘hot spot’ areas a.m. Weidner) gave similar results.
Even if low reproducibility is considered an important problem of
vessel counting (Hlatky et al, 2002), this method is frequently used
in translational angiogenesis research; other methods, including
morphometry, have not proved to be superior.
The study of Valencak et al (2004) included 120 cases of
cutaneous melanoma with follow-up information (median thick-
ness not given; 18% of patients were Clark 0–2, 45% were Clark 4–
5; in comparison, 90% were Clark 4–5 in our own study). By
staining for podoplanin, and using the ‘hot spot’ method of
counting, the mean LVD was 11.3 per field (field size not given),
and this is probably considerably higher than in the other studies.
Increased LVD was associated with decreased survival, but the
difference was only modest and did not persist in multivariate
analysis, in contrast to what we found (Straume et al, 2003). The
use of different markers could be one explanation for the findings,
although LVD by LYVE-1 and podoplanin staining was signifi-
cantly correlated in our previous study. Also, the sensitivity and
specificity of the LYVE-1 antibody were evaluated in a recent study
by Akishima et al (2004).
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consisted of thicker and more advanced primary melanomas than
the other series, consisting of vertical growth phase melanomas
only. This could be an important explanation why the relationship
between LVD and progression/prognosis appears to be different.
Interestingly, we found a significant association between increased
LVD and lymphocytic infiltration, which is a favourable prognostic
factor for cutaneous melanomas, and a similar relationship with
lymphatic vascular area was found by Dadras et al (2003). This
points to a relationship between lymphatic vessels and an
antitumour immune response.
The studies of Dadras et al and Shields et al have included a low
number of pre-selected cases and might not be classified as
prognostic factor studies according to the criteria of Simon and
Altman (1994). For instance, Dadras et al did not present
prognostic information on LVD, but found that relative lymphatic
vessel area was a prognostic factor, although their cut-points
appear to be selected on the basis of a relationship with a strong
predictor of outcome, that is, lymph node metastases (their Figure
6A). The ‘prognostic’ information from these studies should
therefore be interpreted with great care. A summary of studies of
clinical end points according to lymphatic markers in human
cancers has recently been given by Padera et al (2003).
The results of animal studies have suggested that increased
lymphangiogenesis may be important for the frequency of
lymphatic metastasis, and the recent identification of novel
lymphangiogenic factors, like VEGF-C and VEGF-D, has increased
the focus on lymphangiogenesis considerably (Kaipainen et al,
1995; Achen et al, 1998; Skobe et al, 2001; Stacker et al, 2001). Still,
the evidence provided in the literature is not sufficient to conclude
that active lymphangiogenesis play an important role in human
cancer. As for the difference between studies on cutaneous
melanoma, the balance between LVD as a marker of lymphatic
spread, and its association with lymphocytic infiltration and
antitumour immune activity, might differ between early (thinner)
and late stage (thicker) melanomas. Also, the relative contribution
of lymphogenic and hematogenic metastases may be different
between these tumour subgroups. We feel that more survival
studies, following the criteria of Simon and Altman (1994), are
needed before the estimation of lymphangiogenesis is applicable to
clinical decision making and prognostication in melanoma
patients.
REFERENCES
Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K,
Stacker SA (1998) Vascular endothelial growth factor D (VEGF-D) is a
ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF
receptor 3 (Flt4). Proc Natl Acad Sci USA 95: 548–553
Akishima Y, Ito K, Zhang L, Ishikawa Y, Orikasa H, Kiguchi H, Akasaka Y,
Komiyama K, Ishii T (2004) Immunohistochemical detection of human
small lymphatic vessels under normal and pathological conditions using
the LYVE-1 antibody. Virchows Arch 444: 153–157
Birner P, Schindl M, Obermair A, Breitenecker G, Kowalski H, Oberhuber G
(2001) Lymphatic microvessel density as a novel prognostic factor in
early-stage invasive cervical cancer. Int J Cancer 95: 29–33
Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG,
Ellwanger U, Garbe C, Mihm MC, Detmar M (2003) Tumor lymphangio-
genesis: a novel prognostic indicator for cutaneous melanoma metastasis
and survival. Am J Pathol 162: 1951–1960
Hlatky L, Hahnfeldt P, Folkman J (2002) Clinical application of
antiangiogenic therapy: microvessel density, what it does and doesn’t
tell us. J Natl Cancer Inst 94: 883–893
Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH,
Dumont D, Breitman M, Alitalo K (1995) Expression of the fms-like
tyrosine kinase 4 gene becomes restricted to lymphatic endothelium
during development. Proc Natl Acad Sci USA 92: 3566–3570
Padera TP, Boucher Y, Jain RK (2003) Correspondence re: S. Maula et al,
intratumoral lymphatics are essential for the metastatic spread and
prognosis in squamous cell carcinoma of the head and neck. Cancer Res.
63: 1920–1926, (Cancer Res 63: 8555–8556; author reply 8558)
Shields JD, Borsetti M, Rigby H, Harper SJ, Mortimer PS, Levick JR,
Orlando A, Bates DO (2004) Lymphatic density and metastatic spread in
human malignant melanoma. Br J Cancer 90: 693–700
Simon R, Altman DG (1994) Statistical aspects of prognostic factor studies
in oncology. Br J Cancer 69: 979–985
Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi
L, Alitalo K, Claffey K, Detmar M (2001) Induction of tumor
lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat
Med 7: 192–198
Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R,
Jackson DG, Nishikawa Si S, Kubo H, Achen MG (2001) VEGF-D promotes
the metastatic spread of tumor cells via the lymphatics. Nat Med 7: 186–191
Straume O, Jackson DG, Akslen LA (2003) Independent prognostic impact
of lymphatic vessel density and presence of low-grade lymphangiogen-
esis in cutaneous melanoma. Clin Cancer Res 9: 250–256
Valencak J, Heere-Ress E, Kopp T, Schoppmann SF, Kittler H, Pehamberger
H (2004) Selective immunohistochemical staining shows significant
prognostic influence of lymphatic and blood vessels in patients with
malignant melanoma. Eur J Cancer 40: 358–364
Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis
and metastasis – correlation in invasive breast carcinoma. N Engl J Med
324: 1–8
Letter to the Editor
1225
British Journal of Cancer (2004) 91(6), 1224–1225 & 2004 Cancer Research UK